(Q36913503)

17 August 2017

1 reference

title

Development of new antiepileptic drugs: challenges, incentives, and recent advances (English)

1 reference

17 August 2017

Jacqueline French

2

0 references

Emilio Perucca

series ordinal

1

object named as

Emilio Perucca

1 reference

17 August 2017

Meir Bialer

3

1 reference

17 August 2017

language of work or name

1 reference

1 September 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

6

1 reference

17 August 2017

issue

9

1 reference

17 August 2017

page(s)

793-804

1 reference

New antiepileptic drugs that are second generation to existing antiepileptic drugs

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

Valproic Acid: second generation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

Antiepileptic drugs in development

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

Diverse mechanisms of antiepileptic drugs in the development pipeline

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

The new antiepileptic drugs: pharmacological and clinical aspects

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

New antiepileptic drugs currently in clinical trials: is there a strategy in their development?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

The impact of new antiepileptic drugs on the prognosis of epilepsy: seizure freedom should be the ultimate goal

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

Novel anticonvulsant medications in development

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

Discovery of antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

Kindling as a model of drug-resistant partial epilepsy: selection of phenytoin-resistant and nonresistant rats

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

Lamotrigine treatment during amygdala-kindled seizure development fails to inhibit seizures and diminishes subsequent anticonvulsant efficacy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

A new frontier in epilepsy: novel antiepileptogenic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

Novel anticonvulsant drugs targeting voltage-dependent ion channels

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

Idiosyncratic adverse reactions to antiepileptic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

Metabolism of Lamotrigine to a Reactive Arene Oxide Intermediate

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

Stability and comparative metabolism of selected felbamate metabolites and postulated fluorofelbamate metabolites by postmitochondrial suspensions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

Eslicarbazepine Acetate: A Double-blind, Add-on, Placebo-controlled Exploratory Trial in Adult Patients with Partial-onset Seizures

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

Topiramate reduces AMPA-induced Ca(2+) transients and inhibits GluR1 subunit phosphorylation in astrocytes from primary cultures

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

A crossover, add-on trial of talampanel in patients with refractory partial seizures

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

Retigabine: in partial seizures

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

Lacosamide: a review of preclinical properties.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

1 reference

7 January 2021

Rufinamide: Pharmacology, clinical trials, and role in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-A receptor channels

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

1 reference

7 January 2021

Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

Efficacy and safety of Losigamone in partial seizures: a randomized double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

Double-blind, placebo-controlled evaluation of cinromide in patients with the Lennox-Gastaut Syndrome. The Group for the Evaluation of Cinromide in the Lennox-Gastaut Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

Prototype antiepileptic drug clinical development plan

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

Clinical trials of investigational antiepileptic drugs: monotherapy designs.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

Monotherapy trials: presurgical studies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

A workshop on antiepileptic drug monotherapy indications

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

1 reference

7 January 2021

Monotherapy trials with the new antiepileptic drugs: study designs, practical relevance and ethical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

Correlation analysis between anticonvulsant ED50 values of antiepileptic drugs in mice and rats and their therapeutic doses and plasma levels

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

Evaluation of human liver slices and reporter gene assays as systems for predicting the cytochrome p450 induction potential of drugs in vivo in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970215-6

7 January 2021

10.1016/S1474-4422(07)70215-6

Identifiers

DOI

1 reference

17 August 2017

1 reference